Kit Hunter Gordon
Director Ejecutivo en The Summit Group Ltd. .
Perfil
Mr. Kit H.
Gordon is Chairman & Managing Partner at Seraphim Capital (General Partner) LLP.
Mr. Gordon also served on the board at Sirigen Group Ltd.
Cargos activos de Kit Hunter Gordon
Empresas | Cargo | Inicio |
---|---|---|
Seraphim Capital (General Partner) LLP
Seraphim Capital (General Partner) LLP Investment ManagersFinance Seraphim Capital (General Partner) LLP, a subsidiary of YFM Equity Partners LLP, is a venture capital firm founded in 2006. The firm is headquartered in London, the United Kingdom. | Inversor de Capital Privado | 01/09/2006 |
The Summit Group Ltd.
The Summit Group Ltd. Financial ConglomeratesFinance The Summit Group Ltd. provides investment services. The British company was founded in 1985 by Kit Hunter Gordon, who has been the CEO since then. | Director Ejecutivo | 01/01/1985 |
Resources for Autism
Resources for Autism Miscellaneous Commercial ServicesCommercial Services Resources for Autism provides social services. The non-profit company is based in London, UK. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Kit Hunter Gordon.
Empresas | Cargo | Fin |
---|---|---|
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Seraphim Capital (General Partner) LLP
Seraphim Capital (General Partner) LLP Investment ManagersFinance Seraphim Capital (General Partner) LLP, a subsidiary of YFM Equity Partners LLP, is a venture capital firm founded in 2006. The firm is headquartered in London, the United Kingdom. | Finance |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Resources for Autism
Resources for Autism Miscellaneous Commercial ServicesCommercial Services Resources for Autism provides social services. The non-profit company is based in London, UK. | Commercial Services |
The Summit Group Ltd.
The Summit Group Ltd. Financial ConglomeratesFinance The Summit Group Ltd. provides investment services. The British company was founded in 1985 by Kit Hunter Gordon, who has been the CEO since then. | Finance |
- Bolsa de valores
- Insiders
- Kit Hunter Gordon